FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320856261> ?p ?o ?g. }

• W4320856261 endingPage "571" @default.
• W4320856261 startingPage "564" @default.
• W4320856261 abstract "Objective: Evaluate the efficacy and safety of transarterial chemoembolization (TACE) sequential with hepatic arterial infusion chemotherapy (HAIC) and a tyrosine kinase inhibitor (TKI) for unresectable large hepatocellular carcinoma (HCC). Methods: Patients with HCC size > 70 mm were included. They received 1-3 cycles of TACE and sequential HAIC every 3-6 weeks for 2-6 cycles, with each cycle given over a period of 48 hours (oxaliplatin plus fluorouracil/leucovorin). Patients also received sorafenib or lenvatinib beginning at the first TACE cycle and continuing until disease progression. Objective response rate (ORR) at 3 months was the primary endpoint. Progression-free survival (PFS) and safety were the secondary endpoints. Results: From January 2020 to December 2020, 41 patients were included, who were divided into the drug-eluting bead TACE (DEB-TACE) group (n=13) and conventional TACE (cTACE) group (n=28). The overall ORR was 56.1% (23/41) using mRECIST criteria and 34.1% (14/41) using RECIST1.1 criteria. The median PFS of the cohort was 8 months. The ORR of the DEB-TACE group was 76.9% (10/13) vs. 46.4% (13/28) for the cTACE group (p = 0.06). The median PFS of the DEBTACE group was 12 months, and 6 months in the cTACE group (p = 0.09). Conversion hepatectomy was performed in 2 patients in the DEB-TACE group (15.4%), and in 3 patients in the cTACE group (10.7%). ALT/AST elevated, hypertension, nausea, and vomiting were the common treatment related adverse events. There was no treatment related death. Conclusion: TACE sequential with HAIC combined a TKI is a well-tolerated and promising tripletherapy for large, unresectable HCC." @default.
• W4320856261 created "2023-02-16" @default.
• W4320856261 creator A5004653148 @default.
• W4320856261 creator A5007108562 @default.
• W4320856261 creator A5023916892 @default.
• W4320856261 creator A5028798780 @default.
• W4320856261 creator A5037763084 @default.
• W4320856261 creator A5042306963 @default.
• W4320856261 creator A5051735801 @default.
• W4320856261 creator A5067483347 @default.
• W4320856261 date "2023-08-01" @default.
• W4320856261 modified "2023-09-27" @default.
• W4320856261 title "Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma" @default.
• W4320856261 cites W1971837077 @default.
• W4320856261 cites W1975154077 @default.
• W4320856261 cites W1982587280 @default.
• W4320856261 cites W2036304264 @default.
• W4320856261 cites W2052552898 @default.
• W4320856261 cites W2092759077 @default.
• W4320856261 cites W2101459399 @default.
• W4320856261 cites W2125763116 @default.
• W4320856261 cites W2284586115 @default.
• W4320856261 cites W2606094785 @default.
• W4320856261 cites W2624220637 @default.
• W4320856261 cites W2784317233 @default.
• W4320856261 cites W2787358630 @default.
• W4320856261 cites W2789635905 @default.
• W4320856261 cites W2889646458 @default.
• W4320856261 cites W2898647024 @default.
• W4320856261 cites W2902313304 @default.
• W4320856261 cites W2909659250 @default.
• W4320856261 cites W2944033593 @default.
• W4320856261 cites W2977602933 @default.
• W4320856261 cites W2981257152 @default.
• W4320856261 cites W3035757716 @default.
• W4320856261 cites W3045447168 @default.
• W4320856261 cites W3096652041 @default.
• W4320856261 cites W3121032265 @default.
• W4320856261 cites W3121807241 @default.
• W4320856261 cites W3152048863 @default.
• W4320856261 cites W3216160878 @default.
• W4320856261 doi "https://doi.org/10.2174/1568009623666230215142941" @default.
• W4320856261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36790005" @default.
• W4320856261 hasPublicationYear "2023" @default.
• W4320856261 type Work @default.
• W4320856261 citedByCount "1" @default.
• W4320856261 countsByYear W43208562612023 @default.
• W4320856261 crossrefType "journal-article" @default.
• W4320856261 hasAuthorship W4320856261A5004653148 @default.
• W4320856261 hasAuthorship W4320856261A5007108562 @default.
• W4320856261 hasAuthorship W4320856261A5023916892 @default.
• W4320856261 hasAuthorship W4320856261A5028798780 @default.
• W4320856261 hasAuthorship W4320856261A5037763084 @default.
• W4320856261 hasAuthorship W4320856261A5042306963 @default.
• W4320856261 hasAuthorship W4320856261A5051735801 @default.
• W4320856261 hasAuthorship W4320856261A5067483347 @default.
• W4320856261 hasConcept C121608353 @default.
• W4320856261 hasConcept C126322002 @default.
• W4320856261 hasConcept C141071460 @default.
• W4320856261 hasConcept C168563851 @default.
• W4320856261 hasConcept C197934379 @default.
• W4320856261 hasConcept C203092338 @default.
• W4320856261 hasConcept C2776694085 @default.
• W4320856261 hasConcept C2778019345 @default.
• W4320856261 hasConcept C2778375690 @default.
• W4320856261 hasConcept C2778695046 @default.
• W4320856261 hasConcept C2778822529 @default.
• W4320856261 hasConcept C2779984678 @default.
• W4320856261 hasConcept C2780580376 @default.
• W4320856261 hasConcept C2780852908 @default.
• W4320856261 hasConcept C2780962732 @default.
• W4320856261 hasConcept C526805850 @default.
• W4320856261 hasConcept C71924100 @default.
• W4320856261 hasConcept C90924648 @default.
• W4320856261 hasConceptScore W4320856261C121608353 @default.
• W4320856261 hasConceptScore W4320856261C126322002 @default.
• W4320856261 hasConceptScore W4320856261C141071460 @default.
• W4320856261 hasConceptScore W4320856261C168563851 @default.
• W4320856261 hasConceptScore W4320856261C197934379 @default.
• W4320856261 hasConceptScore W4320856261C203092338 @default.
• W4320856261 hasConceptScore W4320856261C2776694085 @default.
• W4320856261 hasConceptScore W4320856261C2778019345 @default.
• W4320856261 hasConceptScore W4320856261C2778375690 @default.
• W4320856261 hasConceptScore W4320856261C2778695046 @default.
• W4320856261 hasConceptScore W4320856261C2778822529 @default.
• W4320856261 hasConceptScore W4320856261C2779984678 @default.
• W4320856261 hasConceptScore W4320856261C2780580376 @default.
• W4320856261 hasConceptScore W4320856261C2780852908 @default.
• W4320856261 hasConceptScore W4320856261C2780962732 @default.
• W4320856261 hasConceptScore W4320856261C526805850 @default.
• W4320856261 hasConceptScore W4320856261C71924100 @default.
• W4320856261 hasConceptScore W4320856261C90924648 @default.
• W4320856261 hasFunder F4320321001 @default.
• W4320856261 hasIssue "7" @default.
• W4320856261 hasLocation W43208562611 @default.
• W4320856261 hasLocation W43208562612 @default.
• W4320856261 hasOpenAccess W4320856261 @default.
• W4320856261 hasPrimaryLocation W43208562611 @default.

• next